Print this page    •   Back to Web version of article

U.S. News
Abbott Cuts Cost of AIDS Drug for Government Programs

May 10, 2011

Abbott Laboratories announced at its annual shareholders meeting it will reduce the price of Kaletra by 8 percent for state AIDS Drug Assistance Programs (ADAPs). The state-run programs for low-income HIV/AIDS patients are struggling to contain costs amid reductions in government spending and increases in demand due to the poor economy.


North Chicago-based Abbott said ADAPs will pay $5,037 per patient per year for the protease inhibitor, a key ingredient in HIV drug cocktails. Miles White, Abbott's chair and CEO, said the drugmaker has not raised the price of Kaletra since 2007. Other companies have increased prices of their AIDS drugs 5 percent to 6 percent annually, he noted.

Meanwhile, cash-strapped states are starting to impose eligibility restrictions on people seeking help through ADAPs. More than 7,700 patients countrywide are on ADAP waiting lists, said the AIDS Healthcare Foundation, citing state and federal data.

In Illinois, the state health department will restrict its ADAP to "new applicants with incomes at or below 300 percent of the federal poverty level," or $32,670 for a single individual, beginning in July. The program currently admits individuals earning 500 percent of the federal poverty level, or $54,450.

Back to other news for May 2011

Excerpted from:
Chicago Tribune
04.29.2011; Bruce Japsen

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.